7 results on '"Sipkins, D"'
Search Results
2. Paramagnetic polymerized liposomes as new recirculating MR contrast agents.
- Author
-
Storrs, Richard W., Tropper, FrançOis D., Li, Henry Y., Song, Curtis K., Sipkins, Dorothy A., Kuniyoshi, Jeremy K., Bednarski, Mark D., Strauss, H. William, Li, King C. P., Storrs, R W, Tropper, F D, Li, H Y, Song, C K, Sipkins, D A, Kuniyoshi, J K, Bednarski, M D, Strauss, H W, and Li, K C
- Published
- 1995
- Full Text
- View/download PDF
3. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging
- Author
-
Sipkins, D. A., Gijbels, K., Tropper, F. D., Bednarski, M., Li, K. C., and Steinman, L.
- Published
- 2000
- Full Text
- View/download PDF
4. PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP/TAZ Pathway.
- Author
-
Fan S, Price T, Huang W, Plue M, Warren J, Sundaramoorthy P, Paul B, Feinberg D, MacIver N, Chao N, Sipkins D, and Kang Y
- Abstract
The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN-induced putative kinase 1 (PINK1)-dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined. The levels of the PINK1-dependent mitophagy markers PINK1 and parkin RBR E3 ubiquitin protein ligase ( PARK2) in CD138
+ plasma cells are reduced in patients with MM and correlate with clinical outcomes in myeloma patients. Moreover, the induction of PINK1-dependent mitophagy with carbonylcyanide- m -chlorophenylhydrazone (CCCP) or salinomycin, or overexpression of PINK1 leads to inhibition of transwell migration, suppression of myeloma cell homing to calvarium, and decreased osteolytic bone lesions. Furthermore, genetic deletion of pink1 accelerates myeloma development in a spontaneous X-box binding protein-1 spliced isoform ( XBP-1s ) transgenic myeloma mouse model and in VK*MYC transplantable myeloma recipient mice. Additionally, treatment with salinomycin shows significant antimyeloma activities in vivo in murine myeloma xenograft models. Finally, the effects of PINK1-dependent mitophagy on myeloma pathogenesis are driven by the activation of the Mps one binder kinase activator (MOB1B)-mediated Hippo pathway and the subsequent downregulation of Yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) expression. These data provide direct evidence that PINK1-dependent mitophagy plays a critical role in the pathogenesis of MM and is a potential therapeutic target., Competing Interests: Y.K. received research funding from InCyte Corporation and Consultancy fee from Takeda Oncology USA. All other authors declare no competing conflicts of interest., (© 2020 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.)- Published
- 2020
- Full Text
- View/download PDF
5. β-Arrestin2 mediates progression of murine primary myelofibrosis.
- Author
-
Rein LA, Wisler JW, Kim J, Theriot B, Huang L, Price T, Yang H, Chen M, Chen W, Sipkins D, Fedoriw Y, Walker JK, Premont RT, and Lefkowitz RJ
- Subjects
- Animals, Apoptosis physiology, Bone Marrow pathology, Cell Proliferation physiology, Disease Models, Animal, Disease Progression, Graft Survival physiology, Hematopoietic Stem Cell Transplantation methods, Hematopoietic Stem Cells metabolism, Male, Mice, Knockout, Primary Myelofibrosis chemically induced, Primary Myelofibrosis pathology, Tamoxifen, beta-Arrestin 2 deficiency, beta-Arrestin 2 genetics, Primary Myelofibrosis metabolism, beta-Arrestin 2 physiology
- Abstract
Primary myelofibrosis is a myeloproliferative neoplasm associated with significant morbidity and mortality, for which effective therapies are lacking. β-Arrestins are multifunctional adaptor proteins involved in developmental signaling pathways. One isoform, β-arrestin2 (βarr2), has been implicated in initiation and progression of chronic myeloid leukemia, another myeloproliferative neoplasm closely related to primary myelofibrosis. Accordingly, we investigated the relationship between βarr2 and primary myelofibrosis. In a murine model of MPLW515L-mutant primary myelofibrosis, mice transplanted with donor βarr2-knockout (βarr2-/-) hematopoietic stem cells infected with MPL-mutant retrovirus did not develop myelofibrosis, whereas controls uniformly succumbed to disease. Although transplanted βarr2-/- cells homed properly to marrow, they did not repopulate long-term due to increased apoptosis and decreased self-renewal of βarr2-/- cells. In order to assess the effect of acute loss of βarr2 in established primary myelofibrosis in vivo, we utilized a tamoxifen-induced Cre-conditional βarr2-knockout mouse. Mice that received Cre (+) donor cells and developed myelofibrosis had significantly improved survival compared with controls. These data indicate that lack of antiapoptotic βarr2 mediates marrow failure of murine hematopoietic stem cells overexpressing MPLW515L. They also indicate that βarr2 is necessary for progression of primary myelofibrosis, suggesting that it may serve as a novel therapeutic target in this disease.
- Published
- 2017
- Full Text
- View/download PDF
6. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
- Author
-
Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, and Stock W
- Subjects
- Acute Disease, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chromosome Aberrations, Combined Modality Therapy, Cytarabine administration & dosage, Cytarabine adverse effects, Diarrhea chemically induced, Dose-Response Relationship, Drug, Female, Hematologic Diseases chemically induced, Humans, Infections etiology, Kaplan-Meier Estimate, Leukemia, Myeloid genetics, Leukemia, Myeloid surgery, Male, Middle Aged, Mitoxantrone administration & dosage, Mitoxantrone adverse effects, Neoplasm Proteins genetics, Neoplasms, Second Primary drug therapy, Neoplasms, Second Primary genetics, Neoplasms, Second Primary surgery, Prognosis, Recurrence, Remission Induction, Retrospective Studies, Risk, Stem Cell Transplantation, Transplantation, Homologous, Young Adult, fms-Like Tyrosine Kinase 3 genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid drug therapy
- Abstract
Patients with high-risk AML, defined as those with advanced age, relapsed/refractory disease, unfavorable molecular and cytogenetic abnormalities, therapy-related myeloid neoplasm (t-MN) and multiple medical co-morbidities tend to respond poorly to standard cytarabine and daunorubicin induction therapy and have a poor prognosis. We performed a retrospective analysis of an alternative induction regimen using high dose cytarabine (HiDAC) and mitoxantrone (MITO) administered to 78 high-risk patients with AML at The University of Chicago from 2001 to 2008. The primary endpoints of the study were complete remission (CR) rate and death within 30 days of initiation of treatment. The median age was 63 years (range:23-85); 27% of these patients had a Charlson co-morbidity index (CCI) > 2. Forty-three (56%) patients had unfavorable cytogenetics, 28 (37%) had intermediate-risk cytogenetics and 5 (7%) had favorable cytogenetics. The CR rate was 45% and the CRi rate 10%; 7 patients (9%) died during induction. Notably, t-MN and relapsed/refractory patients had CR and induction death rates equivalent to de novo AML patients within this series. In this high risk AML population, HiDAC/MITO induction demonstrated an overall response rate of 55% with a low induction death rate of 9% and allowed 32 (41%) patients to proceed to allogeneic stem cell transplant.
- Published
- 2012
- Full Text
- View/download PDF
7. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.
- Author
-
Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, and Li KC
- Subjects
- Animals, Antibodies, Monoclonal, Contrast Media, Molecular Probes, Rabbits, Carcinoma blood supply, Magnetic Resonance Imaging methods, Neovascularization, Pathologic diagnosis, Receptors, Vitronectin isolation & purification
- Abstract
Angiogenesis, the formation of new blood vessels, is a requirement for malignant tumor growth and metastasis. In the absence of angiogenesis, local tumor expansion is suppressed at a few millimeters and cells lack routes for distant hematogenous spread. Clinical studies have demonstrated that the degree of angiogenesis is correlated with the malignant potential of several cancers, including breast cancer and malignant melanoma. Moreover, the expression of a specific angiogenesis marker, the endothelial integrin alphaVbeta3, has been shown to correlate with tumor grade. However, studies of tumor angiogenesis such as these have generally relied on invasive procedures, adequate tissue sampling and meticulous estimation of histologic microvessel density. In the present report, we describe a novel approach to detecting angiogenesis in vivo using magnetic resonance imaging (MRI) and a paramagnetic contrast agent targeted to endothelial alphaVbeta3 via the LM609 monoclonal antibody. This approach provided enhanced and detailed imaging of rabbit carcinomas by directly targeting paramagnetic agents to the angiogenic vasculature. In addition, angiogenic 'hot spots' not seen by standard MRI were detected. Our strategy for MR imaging of alphaVbeta3 thus represents a non-invasive means to assess the growth and malignant phenotype of tumors.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.